Editas Medicine (EDIT)

• Market cap: $211M
• 1 day: -2.70%
• 5 days: -27.17%
• 1 month: 14.55%
• 3 months: 52.73%
• 6 months: 83.94%
• Year to date: 92.37%
• 1 year: -53.51%
• 5 years: -91.77%
• 10 years: -86.15%
• Sector: Healthcare
• Industry: Biotechnology

About: Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Employees: 226

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

97% more call options, than puts

Call options by funds: $668K | Put options by funds: $339K

5% less funds holding

Funds holding: 203 [Q4 2024] → 193 (-10) [Q1 2025]

8.79% less ownership

Funds ownership: 61.83% [Q4 2024] → 53.03% (-8.79%) [Q1 2025]

21% less capital invested

Capital invested by funds: $64.8M [Q4 2024] → $51M (-$13.8M) [Q1 2025]

24% less first-time investments, than exits

New positions opened: 26 | Existing positions closed: 34

25% less repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 59

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $4 59% upside
• Avg. target: $4 59% upside
• High target: $4 59% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Baird Joel Beatty

59% upside $4

Outperform Maintained

13 May 2025